Fosbretabulin is an investigational drug.
There have been 18 clinical trials for Fosbretabulin.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic, and Ovarian Neoplasms. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
There are three hundred and thirty-three US patents protecting this investigational drug and two international patents.